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Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal
adenocarcinoma: a validation study on biopsies and surgical specimens
Aims: To test the validity of diagnostics incorporat-
ing digital image analysis (DIA) for human epidermal
growth factor 2 (HER2) immunohistochemistry (IHC)
in gastro-oesophageal adenocarcinomas, as an alter-
native to current standard diagnostics using manual
scoring.
Methods and results: We included 319 consecutive
gastro-oesophageal adenocarcinomas (232 biopsies
and 87 surgical specimens). DIA was applied to deter-
mine HER2 IHC classification, using both standard
breast cancer (BC) and modified gastro-oesophageal
cancer (GEC) cut-offs. Consensus manual scores were
established by four independent observers. Chro-
mogenic in-situ hybridization (CISH) was performed
on all 2+ cases by manual scoring, DIA or both.
HER2 status was considered positive in 3+ and CISH-
positive 2+ cases. Overall agreement between DIA
and consensus manual scores was 76.5% (weighted
j = 0.66, BC cut-offs) and 85.6% (weighted
j = 0.80, GEC cut-offs). Agreement was similar for
biopsies and surgical specimens. All disagreement
occurred in the manual IHC equivocal cases. DIA
resulted in a reduction of 2+ cases: 75.8% with BC
cut-offs and 46.5% with GEC cut-offs. HER2 status
was positive in 48 cases (15%) with standard diag-
nostics and DIA using GEC cut-offs, and 46 cases
(14.4%) using BC cut-offs (all with CISH in 2+ cases).
Considering standard diagnostics as a reference, DIA
showed 93.8% sensitivity and 99.6% specificity (BC
cut-offs) or 97.9% sensitivity and 99.6% specificity
(GEC cut-offs).
Conclusions: DIA is a reliable and feasible alternative
to manual HER2 IHC scoring in gastro-oesophageal
adenocarcinoma, both in biopsies and surgical speci-
mens, leading to a reduction of 2+ cases for which
subsequent ISH testing is required.
Keywords: digital image analysis (DIA), gastric cancer, human epidermal growth factor 2 (HER2),
immunohistochemistry (IHC), oesophageal cancer
Introduction
Gastro-oesophageal cancers are among the most com-
monly diagnosed cancers worldwide, with 5-year sur-
vival rates of 19–32%.1,2 Adenocarcinoma is the
most common type of both gastric and distal
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oesophageal cancer.3–5 Overexpression of human epi-
dermal growth factor receptor 2 (HER2) occurs in
15–30% of gastro-oesophageal adenocarcinomas.5–9
In this subgroup of patients, targeted anti-HER2 ther-
apy offers an additional treatment modality, which
was shown to improve survival rates in advanced
stages.10,11
HER2 status in gastro-oesophageal cancer is deter-
mined using immunohistochemistry (IHC) and in-situ
hybridization (ISH). IHC membrane staining is scored
semiquantitatively negative (0 or 1+), equivocal (2+)
or positive (3+) using a modified version of the breast
cancer scoring system.12–14 In equivocal cases, addi-
tional ISH is performed to determine HER2 gene
amplification.
Digital image analysis (DIA) has emerged as an
alternative method to classify HER2 IHC. In breast
cancer, a variety of DIA tools in different platforms is
able to determine HER2 status accurately.15–19 DIA
provides an objective and reproducible HER2 classifi-
cation method to support pathologists in daily prac-
tice. DIA is recognized in the American Society of
Clinical Oncology/College of American Pathologists
(ASCO/CAP) guidelines for HER2 in breast cancer as
a diagnostic modality.20 Potentially, DIA can reduce
IHC equivocal (2+) cases, decreasing the number of
cases requiring subsequent ISH.18,19,21 DIA could
offer these same advantages in gastro-oesophageal
cancer. However, present data are limited, with con-
tradictory results in the literature on this subject to
date. Studies have focused predominantly on surgical
specimens, while in clinical practice HER2 status is
often determined on biopsies, as anti-HER2 therapy is
currently used for unresectable (locally advanced or
metastasised) carcinomas.10
The aim of this study was to validate DIA of HER2
IHC in a large cohort of biopsies and surgical speci-
mens of gastro-oesophageal adenocarcinomas. To this
end, DIA results were compared to consensus manual
IHC scores by four independent observers. Further-
more, HER2 status using DIA with ISH on 2+ cases
was compared to HER2 status by standard diagnos-
tics, consisting of consensus manual scoring with ISH
on 2+ cases.
Materials and methods
C A S E S
A total of 321 consecutive gastric and oesophageal
adenocarcinomas, diagnosed from January 2004 to
December 2011 in the Deventer Hospital (the Nether-
lands), were included. Two cases were excluded, as
ISH failed in repeated tests, resulting in a study popu-
lation of 319 cases (Table 1). All patient material
was handled according to the ‘Code of conduct for
health research’ of the Dutch Federation of Biomedi-
cal Scientific Societies.22 Therefore, no additional per-
mission from our Ethics Committee was needed.










Not advanced 130 40.8
Status unknown 24 7.5
Specimens used for HER2 testing
Biopsy 232 72.7








Distal oesophagus 54 16.9





HER2, Human epidermal growth factor 2.
*Metastasised or inoperable locally advanced cancer.
†Primary tumour location according to TNM7 guidelines.
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I M M U N O H I S T O C H E M I S T R Y A N D M A N U A L S C O R I N G
HER2 IHC was performed on whole tissue samples of
biopsies or surgical specimens using the PATHWAY
HER2/neu 4B5 monoclonal antibody (Ventana Medical
Systems, Illkirch, France), following the manufacturer’s
protocol. HER2 was scored using the modified scoring
system for gastro-oesophageal adenocarcinoma by Hof-
mann et al.,12 with additional guidelines by R€uschoff
et al.13,23 (Table 2). Three clinical pathologists (M.M.S.,
M.L. and M.H.) and one resident (T.K.) received train-
ing on this scoring system, as described previously.14
All observers scored all cases independently on glass
slides (M.M.S., M.L. and M.H.) or digital images (T.K).
Manual consensus score was defined as IHC-positive for
a 3+ score by at least two observers (with minimum 2+
by other observers), IHC-negative if all observers scored
0 or 1+ and IHC-equivocal (2+) in all remaining cases.
D I G I T A L I M A G E A N A L Y S I S
Digital images were acquired by scanning the glass
slides in a NanoZoomer 2.0 HT (Hamamatsu Photon-
ics, Hamamatsu City, Shizuoka, Japan) with a 940
magnification lens, using a single focus layer without
Z-stacking. Tissue detection with focus points was
applied automatically. Digitized slides were stored on
a hard disk and loaded into the DIA software module
Visiopharm Integrator System (VIS) platform version
6.5.02303 (Visiopharm, Hørsholm, Denmark).
The HER2-CONNECT algorithm was used to classify
immunohistochemical HER2 staining. This algorithm
analyses membrane staining in a user-selected region
of interest (ROI) by calculating a connectivity value
based on diaminobenzidine (DAB) staining of linear
structures corresponding to membrane fragments, as
described in detail by Br€ugmann et al.19 This connec-
tivity value can vary continuously from 0 to 1, and
is converted to a HER2 classification (0, 1+, 2+ or
3+) with specific cut-offs. The standard breast cancer
(BC) cut-offs,21 as well as modified gastro-oesophageal
cancer (GEC) cut-offs, are displayed in Table 2. These
GEC cut-offs were established with 12 randomly
selected cases, three for each consensus manual score
(two biopsies and one surgical specimen).
ROIs with the most pronounced membrane stain-
ing containing a minimum of 30 tumour cells were
selected; maximum size was 0.5 mm2. Multiple ROIs
were selected: five to 35 ROIs in each case, depending
on tissue size and staining heterogeneity, to ensure
that a representative sample of HER2 expression was
included. In biopsies, ROIs were selected in multiple
sections on multiple levels. Artefacts and non-tumour
tissue staining were carefully avoided, if possible.
The algorithm determines connectivity value for
each individual ROI. In biopsies, the highest connec-
tivity value of a single ROI among all analysed ROIs
was interpreted as representative for the case, in
accordance with the manual scoring guidelines of
requiring a single cluster of ≥5 tumour cells.12,23 In
Table 2. HER2 by manual scoring and digital image analysis classification in gastric and oesophageal adenocarcinoma







0 Negative No reactivity or no membranous
reactivity (visible at 940)
Connectivity = 0 Connectivity = 0
1+ Negative Faint or barely visible
membranous reactivity
(visible at 940)
0 < connectivity ≤0.40 0 < connectivity ≤0.20
2+ Equivocal (requires
subsequent ISH)




0.40 < connectivity ≤0.64 0.20 < connectivity ≤0.64
3+ Positive Strong complete, basolateral or
lateral membranous reactivity
(visible at 92.5–5)
Connectivity >0.64 Connectivity >0.64
HER2, Human epidermal growth factor 2; IHC, Immunohistochemistry; DIA, Digital image analysis; ISH, In-situ hybridization.
*According to the modified scoring system for gastro-oesophageal adenocarcinoma by Hofmann et al.12 with additional guidelines by
R€uschoff et al.13,23 Sufficient well-preserved tumour tissue should be present, staining should be membranous and there should be a cluster
of ≥5 stained tumour cells in biopsies or staining in ≥10% of tumour cells in surgical specimens.
© 2017 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 72, 191–200.
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surgical specimens, positive staining should include
≥10% of all tumour cells, and as such the highest
connectivity score given by the algorithm was verified
visually to be representative of ≥10% of the tumour.
I N - S I T U H Y B R I D I Z A T I O N
ISH was performed on all samples scored or classified
2+ by manual scoring or DIA. Chromogenic in-situ
hybridization (CISH) was performed using ZytoDot
SPEC HER2 Probe kit (ZytoVision, Bremerhaven, Ger-
many), following the manufacturer’s protocol. Nega-
tive CISH was defined as diploidy (two dots per
nucleus) or polysomia (three to five dots per nucleus).
Positive CISH was defined as low amplification (six to
10 dots per nucleus or small clusters) or high amplifi-
cation (>10 dots per nucleus or large clusters) in
>50% of tumour cells in at least 20 cells.
C O M P A R I S O N O F D I A W I T H M A N U A L S C O R I N G
DIA classification of IHC was compared to consensus
manual scores (negative, equivocal or positive) in the
total study population as well as stratified between
biopsies and surgical specimens. The clinically rele-
vant outcome is HER2 status after ISH in 2+ cases.
As such, HER2 status outcome when using DIA with
subsequent CISH on 2+ cases was compared to HER2
status by standard diagnostics, which consisted of
consensus manual scoring with subsequent CISH on
2+ cases. HER2 status was considered positive in IHC
3+ cases or IHC 2+ cases with positive CISH.
S T A T I S T I C A L A N A L Y S I S
To establish agreement between DIA classification and
manual consensus scores of HER2 IHC, linear weighted
kappa (j) statistics were performed in R for Windows
version 3.3.2 (R Foundation for Statistical Computing,
Vienna, Austria), using the ‘irr’ package for j statistics.
j values were interpreted as <0.2, slight; 0.21–0.40,
fair; 0.41–0.60, moderate; 0.61–0.80, substantial; and
0.81–1.00, almost perfect agreement.24
Results
A flowchart of HER2 status as determined by standard
diagnostics and DIA is displayed in Figure 1. DIA images
are shown in Figure 2. Distribution of connectivity val-
ues in 1+, 2+ and 3+ cases is displayed in Figure 3.
Standard diagnostics resulted in HER2-positive status in
48 of 319 cases (15%). DIA with CISH in 2+ cases
resulted in HER2-positive status in 46 cases (14.4%)
with BC cut-offs and 48 cases (15%) with GEC cut-offs.
D I A C L A S S I F I C A T I O N C O M P A R E D T O C O N S E N S U S
M A N U A L S C O R E S
Comparison of consensus manual scores and DIA
classification of IHC in the total study population and
stratified between biopsies and surgical specimens is
outlined in Table 3. In the total study population,
overall agreement was 76.5% (95% confidence inter-
val (CI): 71.5–80.8%, 244 of 319 cases) with BC cut-
offs and 85.6% (95% CI: 81.3–89.0%, 273 of 319
cases) with GEC cut-offs. Using BC cut-offs, kappa
value was j = 0.66 (‘substantial’ agreement). Using
GEC cut-offs, this rose to j = 0.80 (‘substantial’,
nearly ‘almost perfect’ agreement). Kappa values
were similar in biopsies and surgical specimens.
Among biopsies, overall agreement was 73.3% (95%
CI: 67.2–78.6%, 170 of 232 cases) with BC cut-offs
and 83.6% (95% CI: 78.3–87.8%, 194 of 232 cases)
with GEC cut-offs. For surgical specimens, overall
agreement was 85.1% (95% CI: 76.1–91.1%, 74 of
87 cases) and 90.8% (95% CI: 82.9–95.3%, 79 of 87
cases) with BC and GEC cut-offs, respectively.
In the total study population, all 180 cases with a
consensus manual IHC-negative score were classified
as negative by DIA with both cut-offs. Similarly, all
40 cases with a consensus manual 3+ score were
classified as 3+ by DIA with both cut-offs.
D I A I N M A N U A L E Q U I V O C A L C A S E S A N D
C O N C O R D A N C E W I T H C I S H
From the total of 99 cases with a manual equivocal
(2+) IHC score, 2+ cases were reduced by 46 (46.5%)
using DIA with GEC cut-offs. Two cases were
discordant with CISH: one case was false-positive 3+
(CISH-negative) and one case was false-negative 1+
(CISH-positive). Using BC cut-offs, 2+ cases were
reduced by 75 (75.8%), which is 29 more than with
GEC cut-offs, but at the cost of two additional false-
negative cases (both classified 1+). Compared to man-
ual scoring, there were no additional 2+ cases by
DIA.
H E R 2 S T A T U S U S I N G D I A V E R S U S S T A N D A R D
D I A G N O S T I C S
Sensitivity, specificity, positive and negative predictive
value of HER2 status by DIA compared to standard
diagnostics are displayed in Table 4.
© 2017 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 72, 191–200.
































































Figure 1. Flowchart of HER2 status as determined by standard diagnostics with consensus manual scoring (A) and by digital image analysis
classification (B,C), with subsequent CISH on 2+ cases. HER2, Human epidermal growth factor 2; IHC, Immunohistochemistry; CISH, Chro-
mogenic in-situ hybridization; DIA, Digital image analysis; BC, Breast cancer; GEC, Gastro-oesophageal cancer.
© 2017 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 72, 191–200.











with and without membrane
connectivity mark-up.
Classification of 0 (A,B), 1+
(C,D), 2+ in intestinal tumour
type (E,F), 2+ in diffuse
tumour type (G,H) and 3+ (I,J).
Connectivity values were 0 (B),
0.171 (D), 0.256 (F), 0.386
(H) and 0.983 (J). CISH was
negative in the 1+ case and in
both 2+ cases, and positive in
the 3+ case. HER2: human
epidermal growth factor 2;
CISH: chromogenic in-situ
hybridization.
© 2017 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 72, 191–200.
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Discussion
We aimed to validate DIA of HER2 IHC in gastro-
oesophageal tumours, predominantly biopsies. Agree-
ment between DIA classification and manual scores
was high, and similar in surgical specimens and biop-
sies. DIA led to a reduction of 2+ cases. Additionally,
DIA (with ISH on 2+ cases) resulted in high sensitiv-
ity and specificity to establish HER2 status when
compared to standard diagnostics (manual scoring
with ISH on 2+ cases).
To the best of our knowledge, six studies imple-
menting DIA of HER2 in gastro-oesophageal cancer
have been published to date,25–30 four studies of
which compared directly DIA with manual scor-
ing.27–30 Our results were comparable to three stud-
ies.27–29 The first27 and second29 found overall
agreement between DIA and manual scores in 92%
1.000
Distribution of HER2 connectivity values






Cutoff 2+ (BC cutoffs)



























Figure 3. Distribution of HER2
connectivity values in 1+, 2+
and 3+ cases by DIA
(n = 133). HER2, Human
epidermal growth factor 2;
DIA, Digital image analysis;
BC, Breast cancer; GEC,
Gastro-oesophageal cancer.
Table 3. Comparison of HER2 immunohistochemistry manual scores and digital image analysis classification in the total
study population, biopsies and surgical specimens
Digital image analysis
Consensus manual score
Total study population Biopsies Surgical specimens
0/1+ 2+ 3+ Total 0/1+ 2+ 3+ Total 0/1+ 2+ 3+ Total
BC cut-offs
0/1+ 180 71 0 251 117 59 0 176 63 12 0 75
2+ 0 24 0 24 0 19 0 19 0 5 0 5
3+ 0 4 40 44 0 3 34 37 0 1 6 7
Total 180 99 40 319 117 81 34 232 63 18 6 87
Kappa* j = 0.66 j = 0.65 j = 0.69
GEC cut-offs
0/1+ 180 42 0 222 117 35 0 152 63 7 0 70
2+ 0 53 0 53 0 43 0 43 0 10 0 10
3+ 0 4 40 44 0 3 34 37 0 1 6 7
Total 180 99 40 319 117 81 34 232 63 18 6 87
Kappa* j = 0.80 j = 0.78 j = 0.82
HER2, Human epidermal growth factor 2; BC, Breast cancer; GEC, Gastro-oesophageal cancer.
*Linear weighted kappa (j) score.
© 2017 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 72, 191–200.
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of 103 cases (95% CI: 85.4–96.0%) and 97% of 68
cases (95% CI: 90.0–99.2%), respectively, which is
comparable to the 85.6% (95% CI: 81.3–89.0%)
overall agreement we found (using GEC cut-offs). A
third study28 on 110 cases reports 76% sensitivity of
DIA with BC cut-offs, 100% with their GEC cut-offs
and 100% specificity with both cut-offs when com-
pared to ISH. We found similar results: 93.8% sensi-
tivity with BC cut-offs, 97.9% with GEC cut-offs and
specificity 99.6% with both cut-offs when compared
to standard diagnostics. They performed ISH on all
cases and we performed ISH only when clinically
applicable (2+ cases). The fourth study by Jeung
et al.30 on 116 cases found 100% agreement between
DIA and manual IHC-negative cases (also 100% in
our study), 20–50% agreement in 3+ cases (100% in
our study) and 0% agreement in 2+ cases, the latter
being lower than, but in line with, the reduction of
2+ cases in our study. ISH was not performed in their
study. As addressed by the authors, their algorithm
was optimized for breast cancer and consequently
unable to classify membrane staining adequately in
gastro-oesophageal cancer. Although the algorithm
in the current study was also developed for breast
cancer, agreement of DIA with manual scores was
high nonetheless.
As anti-HER2 therapy is used currently for unre-
sectable gastro-oesophageal cancers, in clinical prac-
tice HER2 status is often determined on biopsies.10
However, only two studies included biopsies besides
surgical specimens.29,30 Ormenisan et al.29 found
Table 4. HER2 status using digital image analysis com-
pared to standard diagnostics
Digital image
analysis
Standard diagnostics (consensus manual scoring
with ISH in 2+ cases)
Negative Positive Total
BC cut-offs (with ISH in 2+ cases)
Negative 270 3 273 NPV: 98.9%
Positive 1 45 46 PPV: 97.8%
Total 271 48 319
Spec: 99.6% Sens: 93.8%
GEC cut-offs (with ISH in 2+ cases)
Negative 270 1 271 NPV: 99.6%
Positive 1 47 48 PPV: 97.9%
Total 271 48 319
Spec: 99.6% Sens: 97.9%
HER2, Human epidermal growth factor 2; ISH, In-situ hybridiza-
tion; BC, Breast cancer; GEC, Gastro-oesophageal cancer; Spec,
Specificity; Sens, Sensitivity; PPV, Positive predictive value; NPV,
Negative predictive value.
A B C D
E F G H
Figure 4. Artefacts and staining of non-tumour tissue with HER2 immunohistochemistry. There is immunoreactivity with normal gastric
epithelium (A), intestinal metaplasia (B) and dysplastic epithelium (C). Aberrant staining can occur in edge artefacts (D). The false-positive
(E,F) and false-negative (G,H) cases of this study illustrate artefactual nuclear and cytoplasmic staining, complicating manual and digital
evaluation (images with and without membrane connectivity mark-up). Connectivity values of the discordant cases were 0.819 (F) and
0.147 (H). HER2: human epidermal growth factor 2.
© 2017 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 72, 191–200.
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high agreement in both biopsies and surgical speci-
mens, but in a substantially smaller cohort (68 cases)
than our study. Jeung et al.30 found most disagree-
ment among biopsies, while in the current study
agreement rates in biopsies and surgical specimens
were similar. The authors attribute this to the fact
that in biopsies only a small number of HER2-positive
cells are required,12,23 which did not reach the
threshold for a positive result in their DIA algorithm.
As we used ROIs centred on positive clusters, this
issue did not arise in our study.
In breast cancer, DIA can reduce the amount of
IHC-equivocal (2+) cases.18,19,21 In gastro-oesopha-
geal cancer, Nielsen et al.28 reported 36.4% reduction
of 2+ cases using HercepTest and 50% reduction
using the 4B5 antibody. In the current study, using
4B5 and applying GEC cut-offs, a 46.5% reduction of
2+ cases was achieved, which confirms these results.
The reduction of 2+ cases decreases the need for sub-
sequent ISH testing, potentially lowering diagnostic
costs and reducing turnaround time in daily practice.
Three CISH-positive cases were classified false-nega-
tively as 1+ when using BC cut-offs. In two of these
cases, GEC cut-offs resulted in a 2+ classification,
which would have triggered subsequent CISH. The
third case was also a false-negative 1+ with GEC cut-
offs. Upon review, manual scoring was complicated
due to aberrant staining in nuclei and cytoplasm.
Membrane staining was faint, and only one observer
scored 2+; the other three scored negative. Addition-
ally, the tumour was a diffuse type, on which HER2
scoring is known to be difficult.5 One CISH-negative
case was classified false-positively as 3+ due to strong
aberrant cytoplasmic staining, which could not be
avoided when selecting ROIs as all tumour tissue
expressed aberrant staining. This case was scored
manually as 0 by three and 3+ by one observer, who
also interpreted the aberrant staining as positive mem-
brane staining. As such, when using DIA with GEC
cut-offs to determine HER2 status in our study popula-
tion, only two of 319 cases (0.6%) were classified dis-
cordantly. In both cases manual scoring was
troublesome, due partly or entirely to flawed staining.
Aberrant staining can occur as nuclear or cytoplasmic
staining, edge artefacts or crushing artefacts.30–32
Cytoplasmic staining with the 4B5 antibody could be
related to cross-reactivity with HER4.33 Additionally,
immunoreactivity can occur in pre-existent epithelium
and pre-neoplastic tissue (intestinal metaplasia and
dysplasia).25 Interestingly, this occurred in all our
cases if such tissue was present. Figure 4 displays
examples of aberrant staining and images of the
discordant cases. When conducting DIA, artefacts and
aberrant staining should be avoided carefully.
HER2 membrane staining does not have to be cir-
cumferential in gastro-oesophageal cancer, as in
breast cancer.20 Although the algorithm we used
evaluates membrane connectivity, both Nielsen
et al.28 and our team found that it can be applied
successfully to gastro-oesophageal cancer specimens.
We established GEC cut-offs at connectivity values of
0.20 (1+ to 2+) and 0.64 (2+ to 3+), but GEC cut-offs
by Nielsen et al. were notably lower (0.09 and 0.30).
This could be related to ROI size, as they selected
entire tissue microarray images and HER2 classifica-
tion is based on the membrane connectivity within
the complete ROI. We used relatively small ROIs con-
taining the strongest HER2 expression, as only five
clustered positive tumour cells are required.12,23
The adjusted GEC cut-offs in this study were estab-
lished on samples processed and stained in one labo-
ratory. Further studies should be performed to
validate these cut-offs, including stains from other
laboratories and different HER2 antibodies. Although
appropriate staining and training protocols have led
to acceptable interobserver and interlaboratory con-
cordance, manual scoring remains a subjective
method with interobserver variability.14,34 DIA could
provide an objective and reproducible alternative, but
no data are available on interplatform variability
between different DIA platforms on identical cases.
In conclusion, our data suggest that DIA is a reli-
able and feasible alternative to manual scoring of
HER2 immunohistochemistry in gastro-oesophageal
adenocarcinoma, which can reduce equivocal cases
requiring subsequent ISH testing and can be applied
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